| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Gen Counsel & Corp Sec | SVP, Gen Counsel & Corp Sec
1 company
Mikhail Eydelman last filed a Form 4 in March 2025, as SVP, Gen Counsel & Corp Sec at PCVX. From June 2022 to March 2025, the filings on record show 0 open-market purchases and 18 sales. Mikhail Eydelman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Mikhail Eydelman's trades have earned a middling insider score of 67/100 across 18 rated trades. Over a 12-month horizon, 72.2% of those trades were profitable, with an average 12-month return of +26.0%.
At the last filing, the largest reported position was 41,620 shares of PCVX. The PCVX filings lean toward selling, a net 80,503 shares.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $72.06 | $120,127.22 | -5.1% | +52.5% | -52.0% | |
| May 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $61.74 | $102,921.27 | -5.2% | +25.4% | -44.7% | |
| Apr 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $66.73 | $111,234.14 | -5.2% | +15.3% | -51.7% | |
| Mar 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $73.73 | $122,906.84 | -5.1% | -2.1% | +1.8% | |
| Feb 1, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $73.87 | $123,143.91 | -7.4% | -15.6% | +16.9% | |
| Jan 2, 2024 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 1,667 | $63.93 | $106,578.89 | -7.4% | +6.0% | +32.3% | |
| Dec 7, 2023 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 10,000 | $56.50 | $565,000.00 | -32.2% | +25.4% | +64.3% | |
| Oct 2, 2023 | PCVX Vaxcyte, Inc. | SVP, Gen Counsel & Corp Sec | Sale+OE10b5-1 | 20,000 | $50.40 | $1,007,988.60 | -49.4% | +28.3% | +135.6% |